How did the company's financial position change during 2024?

Cash, cash equivalents and marketable securities rose to $2.29 billion at December 31, 2024, from $1.85 billion a year earlier, primarily due to the December 2024 public equity offering that raised $823 million in net proceeds. Total assets were $2.56 billion and total stockholders' equity was $2.27 billion at year-end.

What drove the increase in operating expenses?

Research and development expenses increased to $592.2 million for 2024 from $423.1 million, mainly due to higher clinical trial expenses for daraxonrasib, elironrasib and zoldonrasib, higher personnel costs, and higher stock-based compensation. General and administrative expenses rose to $97.3 million from $75.6 million, primarily from commercial preparation activities and personnel-related expenses.

What are the key clinical catalysts for the next year or two?

The company expects to substantially complete enrollment in the RASolute 302 Phase 3 pancreatic cancer trial in 2025, with a data readout expected in 2026. It expects to share additional clinical data on zoldonrasib in the second quarter of 2025 and plans to initiate two additional pivotal pancreatic cancer trials in the second half of 2025.

What is the company's commercial strategy?

The company plans to retain control of U.S. commercial rights as a core element of its strategy, is continuing to add commercial talent including U.S. field teams, and is exploring strategies for serving patients outside the U.S., potentially including partnership opportunities.

What does the company expect for 2025 spending and cash runway?

The company expects a 2025 GAAP net loss between $840 million and $900 million, including estimated non-cash stock-based compensation of $115 million to $130 million. Based on its current operating plan, it projects current cash, cash equivalents and marketable securities can fund planned operations into the second half of 2027.

RVMD/RVMDW 8-K: Earnings & Results

01—Abstract

Summary

Summary of the 8-K filed February 26, 2025. Cited figures are marked; the original filing is the authoritative source.

Revolution Medicines, Inc. reported financial results for the quarter and year ended December 31, 2024, and provided an update on corporate progress in a press release furnished as Exhibit 99.1.

For the full year 2024, the company reported zero total revenue (compared to $11.6 million^a in 2023, a decline attributed to the termination of its Sanofi collaboration in 2023), research and development expenses of $592.2 million (up from $423.1 million), general and administrative expenses of $97.3 million (up from $75.6 million), and a net loss of $600.1 million (up from $436.4 million). For the fourth quarter, net loss was $194.6 million versus $161.5 million a year earlier. Cash, cash equivalents and marketable securities were $2.3 billion at December 31, 2024, up from $1.9 billion, primarily reflecting an upsized public equity offering in December 2024 that raised $823 million in net proceeds.

The company's near-term focus is on its RAS(ON) inhibitor pipeline, led by daraxonrasib. It anticipates substantially completing enrollment in the Phase 3 RASolute 302 trial in previously treated metastatic pancreatic cancer during 2025, with an expected data readout in 2026. It is activating sites for the Phase 3 RASolve 301 trial in previously treated non-small cell lung cancer, and anticipates initiating two additional pivotal trials of daraxonrasib in earlier lines of pancreatic cancer treatment in the second half of 2025.

Management stated it plans to retain control of U.S. commercial rights while preparing for a potential launch, and is exploring strategies for serving patients outside the U.S. For 2025, the company expects a full-year GAAP net loss between $840 million^b and $900 million, including estimated non-cash stock-based compensation of $115 million to $130 million. It projects that current cash, cash equivalents and marketable securities can fund planned operations into the second half of 2027.

02—Key points

Key Highlights

FY2024 net loss of $600.1 million, versus $436.4 million in FY2023; R&D expenses rose to $592.2 million from $423.1 million.
Total revenue was zero in 2024, compared with $11.6 million in 2023, due to the termination of the Sanofi collaboration in 2023.
Cash, cash equivalents and marketable securities of $2.3 billion at December 31, 2024, supported by an upsized December 2024 equity offering with $823 million in net proceeds.
Phase 3 RASolute 302 (daraxonrasib, previously treated metastatic pancreatic cancer): substantial enrollment completion expected in 2025, with data readout expected in 2026.
Phase 3 RASolve 301 (daraxonrasib vs. docetaxel, previously treated RAS mutant NSCLC): study sites being activated.
Two additional pivotal daraxonrasib trials in earlier-line pancreatic cancer (first-line metastatic and adjuvant resectable PDAC) anticipated to begin in the second half of 2025.
2025 guidance: GAAP net loss of $840 million to $900 million; cash expected to fund operations into the second half of 2027.

03—Questions

Frequently Asked Questions

How did the company's financial position change during 2024?
Cash, cash equivalents and marketable securities rose to $2.29 billion at December 31, 2024, from $1.85 billion a year earlier, primarily due to the December 2024 public equity offering that raised $823 million in net proceeds. Total assets were $2.56 billion and total stockholders' equity was $2.27 billion at year-end.
What drove the increase in operating expenses?
Research and development expenses increased to $592.2 million for 2024 from $423.1 million, mainly due to higher clinical trial expenses for daraxonrasib, elironrasib and zoldonrasib, higher personnel costs, and higher stock-based compensation. General and administrative expenses rose to $97.3 million from $75.6 million, primarily from commercial preparation activities and personnel-related expenses.
What are the key clinical catalysts for the next year or two?
The company expects to substantially complete enrollment in the RASolute 302 Phase 3 pancreatic cancer trial in 2025, with a data readout expected in 2026. It expects to share additional clinical data on zoldonrasib in the second quarter of 2025 and plans to initiate two additional pivotal pancreatic cancer trials in the second half of 2025.
What is the company's commercial strategy?
The company plans to retain control of U.S. commercial rights as a core element of its strategy, is continuing to add commercial talent including U.S. field teams, and is exploring strategies for serving patients outside the U.S., potentially including partnership opportunities.
What does the company expect for 2025 spending and cash runway?
The company expects a 2025 GAAP net loss between $840 million and $900 million, including estimated non-cash stock-based compensation of $115 million to $130 million. Based on its current operating plan, it projects current cash, cash equivalents and marketable securities can fund planned operations into the second half of 2027.

04—Continue

← View all 8-K filings